Download PDF
Thromb Haemost 2012; 107(03): 592-594
DOI: 10.1160/TH11-09-0625
Letters to the Editor
Schattauer GmbH

A short half-life of the administered factor XIII (FXIII) concentrates after the first replacement therapy in a newborn with severe congenital FXIII deficiency

Noriko Fujii
1   Department of Pediatrics, Fukuchiyama City Hospital, Fukuchiyama, Japan
,
Masayoshi Souri
2   Department of Molecular Patho-Biochemistry and Patho-Biology, Yamagata University School of Medicine, Yamagata, Japan
,
Akitada Ichinose
2   Department of Molecular Patho-Biochemistry and Patho-Biology, Yamagata University School of Medicine, Yamagata, Japan
› Author Affiliations
Further Information

Publication History

Received: 12 September 2011

Accepted after minor revision: 01 January 2011

Publication Date:
22 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Ichinose A. Physiopathology and regulation of factor XIII. Thromb Haemost 2001; 86: 57-65.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Karimi M, Bereczky Z, Cohan N. et al. Factor XIII Deficiency. Semin Thromb Hemost 2009; 35: 426-438.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Kohler HP, Ichinose A, Seitz R. et al. on behalf of the Factor XIII and Fibrinogen SSC Subcommittee of the ISTH. Diagnosis and classification of factor XIII deficiencies. J Thromb Haemost. 2011 09. 1404-1406.
    PubMedGoogle Scholar
  • 4 Anwar R, Miloszewski KJ. Factor XIII deficiency. Br J Haematol 1999; 107: 468-484.
    CrossrefPubMedGoogle Scholar
  • 5 Biswas A, Ivaskevicius V, Seitz R. et al. An update of the mutation profile of Factor 13 A and B genes. Blood Rev 2011; 25: 193-204.
    CrossrefPubMedGoogle Scholar
  • 6 Lusher J, Pipe SW, Alexander S. et al. Prophylactic therapy with Fibrogammin P is associated with a decreased incidence of bleeding episodes: a retrospective study. Haemophilia 2010; 16: 316-321.
    CrossrefPubMedGoogle Scholar
  • 7 Dreyfus M, Arnuti B, Beurrier P. et al. Safety and efficacy of Fibrogammin P® for the treatment of patients with severe FXIII deficiency. J Thromb Haemost 2003; 01 (Suppl. 01) P0299.
    PubMedGoogle Scholar
  • 8 Nugent DJ. Prophylaxis in rare coagulation disorders -- factor XIII deficiency. Thromb Res 2006; 118 (Suppl. 01) S23-28.
    CrossrefPubMedGoogle Scholar
  • 9 Schroeder V, Durrer D, Meili E. et al. Congenital factor XIII deficiency in Switzerland: from the worldwide first case in 1960 to its molecular characterisation in 2005. Swiss Med Wkly 2007; 137: 272-278.
    PubMedGoogle Scholar
  • 10 Ichinose A. Hemorrhagic Acquired Factor XIII (13) Deficiency and Acquired Hemorrhaphilia 13 Revisited. Semin Thromb Hemost 2011; 37: 382-388.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Shirahata A, Nakamura T, Shiiki M. Pathophysiology of Coagulation in the Newborn Infant. Rinsho Ketsueki 1987; 28: 1065-1074.
    PubMedGoogle Scholar
  • 12 Shirahata A, Nakamura T, Shimono M. et al. Blood coagulation findings and the efficacy of factor XIII concentrate in premature infants with intracranial hemorrhages. Thromb Res 1990; 57: 755-763.
    CrossrefPubMedGoogle Scholar
  • 13 Pinacho A, Páramo JA, Ezcurdia M. et al. Evaluation of the fibrinolytic system in full-term neonates. Int J Clin Lab Res 1995; 25: 149-152.
    CrossrefPubMedGoogle Scholar
  • 14 Anwar R, Minford A, Gallivan L. et al. Delayed umbilical bleeding--a presenting feature for factor XIII deficiency: clinical features, genetics, and management. Pediatrics 2002; 109: E32.
    CrossrefPubMedGoogle Scholar
  • 15 Gootenberg JE. Factor concentrates for the treatment of factor XIII deficiency. Curr Opin Hematol 1998; 05: 372-375.
    CrossrefPubMedGoogle Scholar
  • 16 Hsieh L, Nugent D. Factor XIII deficiency. Haemophilia 2008; 14: 1190-1200.
    CrossrefPubMedGoogle Scholar
  • 17 Fear JD, Miloszewski KJ, Losowsky MS. The half life of factor XIII in the management of inherited deficiency. Thromb Haemost 1983; 49: 102-105.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Sugimura T, Tanaka A, Sato T. et al. Study on BI71.023 (XIII factor concentrated pharmaceutical of Pasteur method processing blood plasma derivation) of in vivo recovery percentage and half time in congenital XIII factor deficiency patient. J New Rem Clin 1993; 42: 1368-1375.
    PubMedGoogle Scholar
  • 19 Brackmann HH, Egbring R, Ferster A. et al. Pharmacokinetics and tolerability of factor XIII concentrates prepared from human placenta or plasma: a crossover randomised study. Thromb Haemost 1995; 74: 622-625.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Lovejoy AE, Reynolds TC, Visich JE. et al. Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency. Blood 2006; 108: 57-62.
    CrossrefPubMedGoogle Scholar
  • 21 Theusinger OM, Baulig W, Asmis LM. et al. In vitro factor XIII supplementation increases clot firmness in Rotation Thromboelastometry (ROTEM). Thromb Haemost 2010; 104: 385-391.
    Article in Thieme ConnectPubMedGoogle Scholar